TY - JOUR
T1 - Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease
AU - Liu, Rui
AU - Umbach, David M.
AU - Tröster, Alexander I.
AU - Huang, Xuemei
AU - Chen, Honglei
N1 - Funding Information:
Parkinson's Progression Markers Initiative, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Élan, GE Healthcare, Genentech, GSK-GlaxoSmithKline, Lilly, Merck, MSD-Meso Scale Discovery, Piramal, Pfizer, Roche, and UCB (www.ppmi-info.org/fundingpartners). This work was supported by the Intramural Research Program of the National Institutes of Health, the National Institute of Environmental Health Sciences (Z01-ES-101986). The study is also in part supported by National Institute of Neurological Disorders and Stroke (NS082151 to XH), from the National Institute of Environmental Health Sciences (ES019672 to XH) and Penn State College of Medicine Translational Brain Research Center. HC is supported by a start-up fund from Michigan State University (GE100455), the Parkinson's Foundation (Grant No. PF-IMP-1825), and the Office of the Assistant Secretary of Defense for Health Affairs, through the Parkinson's Research Program (Award No. W81XWH-17-1-0536), and the National Institute of Environmental Health Sciences (R01ES029227). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense and the National Institutes of Health.
Funding Information:
Dr. Tröster has received royalties from Oxford University Press, grant funding from Barrow Neurological Foundation and served on scientific advisory boards of Medtronic and Takeda. None reported for other authors.
Funding Information:
Parkinson's Progression Markers Initiative, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Élan, GE Healthcare, Genentech, GSK-GlaxoSmithKline, Lilly, Merck, MSD-Meso Scale Discovery, Piramal, Pfizer, Roche, and UCB ( www.ppmi-info.org/fundingpartners ). This work was supported by the Intramural Research Program of the National Institutes of Health , the National Institute of Environmental Health Sciences ( Z01-ES-101986 ). The study is also in part supported by National Institute of Neurological Disorders and Stroke ( NS082151 to XH), from the National Institute of Environmental Health Sciences ( ES019672 to XH) and Penn State College of Medicine Translational Brain Research Center . HC is supported by a start-up fund from Michigan State University ( GE100455 ), the Parkinson's Foundation (Grant No. PF-IMP-1825 ), and the Office of the Assistant Secretary of Defense for Health Affairs, through the Parkinson’s Research Program (Award No. W81XWH-17-1-0536 ), and the National Institute of Environmental Health Sciences ( R01ES029227 ). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense and the National Institutes of Health.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/3
Y1 - 2020/3
N2 - Background: Non-motor symptoms (NMS) are common in Parkinson's disease (PD), but their relationships to nigrostriatal degeneration remain largely unexplored. Methods: We evaluated 18 NMS scores covering 5 major domains in relation to concurrent and future dopamine transporter (DAT) imaging in 344 PD patients from the Parkinson's Progression and Markers Initiative (PPMI). We standardized NMS assessments into z-scores for side-by-side comparisons. Patients underwent sequential DaTSCAN imaging at enrollment and at months 12, 24, and 48. Specific binding ratios (SBR) were calculated using the occipital lobe reference region. We evaluated the association of striatal DAT binding at the four time points with each baseline NMS using mixed-effects regression models. Results: Multiple baseline NMS were significantly associated with DAT binding at baseline and at follow-up scans. REM sleep behavior disorder (RBD) symptoms showed the strongest association – mean striatal SBR declined with increasing RBD symptom z-score (average of time-point-specific slopes per unit change in z-score: βAVG = −0.083, SE = 0.017; p < 0.0001). In addition, striatal DAT binding was linearly associated with increasing baseline z-scores: positively for the memory (βAVG=0.055, SE = 0.022; p = 0.01) and visuospatial (βAVG=0.044, SE = 0.020; p = 0.03) cognitive domains, and negatively for total anxiety (βAVG= −0.059, SE = 0.018; p = 0.001). Striatal DAT binding showed curvilinear associations with odor identification, verbal discrimination recognition, and autonomic dysfunction z-scores (p = 0.001, p = 0.0009, and p = 0.0002, respectively). Other NMS were not associated with DAT binding. Conclusions: Multiple NMS, RBD symptoms in particular, are associated with nigrostriatal dopaminergic changes in early PD.
AB - Background: Non-motor symptoms (NMS) are common in Parkinson's disease (PD), but their relationships to nigrostriatal degeneration remain largely unexplored. Methods: We evaluated 18 NMS scores covering 5 major domains in relation to concurrent and future dopamine transporter (DAT) imaging in 344 PD patients from the Parkinson's Progression and Markers Initiative (PPMI). We standardized NMS assessments into z-scores for side-by-side comparisons. Patients underwent sequential DaTSCAN imaging at enrollment and at months 12, 24, and 48. Specific binding ratios (SBR) were calculated using the occipital lobe reference region. We evaluated the association of striatal DAT binding at the four time points with each baseline NMS using mixed-effects regression models. Results: Multiple baseline NMS were significantly associated with DAT binding at baseline and at follow-up scans. REM sleep behavior disorder (RBD) symptoms showed the strongest association – mean striatal SBR declined with increasing RBD symptom z-score (average of time-point-specific slopes per unit change in z-score: βAVG = −0.083, SE = 0.017; p < 0.0001). In addition, striatal DAT binding was linearly associated with increasing baseline z-scores: positively for the memory (βAVG=0.055, SE = 0.022; p = 0.01) and visuospatial (βAVG=0.044, SE = 0.020; p = 0.03) cognitive domains, and negatively for total anxiety (βAVG= −0.059, SE = 0.018; p = 0.001). Striatal DAT binding showed curvilinear associations with odor identification, verbal discrimination recognition, and autonomic dysfunction z-scores (p = 0.001, p = 0.0009, and p = 0.0002, respectively). Other NMS were not associated with DAT binding. Conclusions: Multiple NMS, RBD symptoms in particular, are associated with nigrostriatal dopaminergic changes in early PD.
UR - http://www.scopus.com/inward/record.url?scp=85079694599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079694599&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2020.02.001
DO - 10.1016/j.parkreldis.2020.02.001
M3 - Article
C2 - 32092703
AN - SCOPUS:85079694599
SN - 1353-8020
VL - 72
SP - 23
EP - 30
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -